Combined Albumin Polyester Nanocarriers with Docetaxel for Effective Against Lung Cancer in Mice Model
This study introduces FA-DTX-APs, an innovative nanocarrier characterized by exceptional biocompatibility and safety. It successfully targets lung cancer cells to deliver DTX in a sustained, slow-release manner, ensuring prolonged tumor-killing effects. As such, FA-DTX-APs hold immense promise as a novel nanoagent for lung cancer therapy.
Authors
- Shengli He (ORCID: https://orcid.org/0000-0003-0548-2478)
- Fusheng Shang (ORCID: https://orcid.org/0000-0002-8727-8077)
- Yixiao Yang (ORCID: https://orcid.org/0009-0001-1527-7526)
- Dagui Chen (ORCID: https://orcid.org/0000-0001-9987-678X)
- Kai Wang (ORCID: https://orcid.org/0000-0002-1373-579X)
- Ye Tao (ORCID: https://orcid.org/0000-0002-5547-6001)
Institutions
- Shanghai University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital (CN)
- The Second Nanning People's Hospital (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/ijn.s487344
- Citations
- 3
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.79